| CN

Devoted to developing innovative gene and cell therapies for curing malignant tumors

MORE

Innovative technical platforms and a variety of pipelines

"One-stop" gene and cell platforms, covering all core technologies for CAR-T cell production

MORE

Advisory Center

Access to Advisory Center
2024-10-29

Imunopharm Receives Clinical Trial Approval for CAR-T Drug to Treat Systemic Lupus Erythematosus
2024-10-12

China's First | Imunopharm Receives Clinical Trial Approval for CAR-T Drug in Metastatic Colorectal Cancer
2020-05-27

Immunochina and Edigene announce that they will jointly develop an allogeneic CAR-T therapy for cancer
2020-04-21

Immunochina obtained approval of clinical trial for IM19 CAR-T cells treatment for refractory or relapse acute B-cell lymphoblastic leukemia
2020-04-15

Immunochina obtained approval of clinical trial for IM19 CAR-T cells treatment for refractory or relapse non-Hodgkin’s lymphoma
2019-10-02

Immunochina and Peking University Cancer Hospital participated in the ESMO 2019 annual meeting and showcased the latest progress in CAR-T research
2019-09-26

Immunochina won the "2019 China Top 50 Healthcare Innovation Enterprises"
2019-08-12

Immunochina was named as the star list-2019 China's top 50 biomedical companies with the most innovative power
2019-08-09

Immunochina and Sijiqing County Exchange Forum
2019-07-23

Mr. Qi Xiaowen, former head of the registration department of Sanofi Pasteur, joined Immunochina
2019-03-23

DeepTech 2019 Life Science Forum was held in Shanghai, Immunochina’s Chairman, Dr. He Ting was awarded the 2019 Life Science Innovation Figure
2018-12-10

Dr. He Ting, CEO of Immunochina, was invited to participate in the 60th American Hematology Annual Meeting (ASH)
2018-11-28

The joint laboratory of Immunochina and Sartorius is officially launched- this cooperation opened a new chapter in cell therapy
2018-11-12

Immunochina was invited to participate in the "2018 China Research Hospital Association and China Disease Cell/Biotherapy Conference"
2018-09-21

Immunochina won the 2018 Billboard • China's 50 Most Valuable Investment Enterprises
2018-08-08

Immunochina CAR-T therapy for new indication’s submission was officially accepted by CFDA
2018-06-04

Immunochina CAR-T therapy clinical data unveiled at ASCO: 3-month complete remission rate of 86%
2018-05-28

Chairman of Immunochina, Dr. He Ting, gave general assembly speech and announced donation feedback for Tsinghua x-lab on the fifth anniversary since Tsinghua x-lab’s establishment
2018-05-25

Immunochina became one of the 10 most noteworthy innovative pharmaceuticals companies in China in 2018
2018-05-07

Immunochina and Thermo Fisher Scientific to realize the digitization of cell therapy sample tracking
2018-04-17

The latest progress in the treatment of advanced leukemia from Immunochina
2018-03-26

Immunochina’s CD19 CAR-T joins hands with Lu Daopei Hospital to shine at the 44th European Society of Blood and Marrow Transplantation Annual Meeting
2017-11-23

Immunochina completes Series B funding to further improve the research and development of cancer gene cell drugs to benefit more patients

Join Us

Imunopharm is looking forward to having you together to fight against cancer!

MORE

Follow Us

010-62886890

B1 District, Yiyuan Cultural and Creative Industry Base, No. 65, Xingshikou Road, Haidian District, Beijing

office@imunopharm.com

www.imunopharm.com

Imunopharm Technology Co., Ltd.
ICP:15031757-1

SUPPORT：YCXF